TUDCA

Strong evidence for cholestatic liver disease and ER stress reduction. Increasingly popular in longevity and liver-support protocols.

A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.

Approved in some countries for cholestatic liver disease. Clinical trials support use in primary biliary cholangitis and intrahepatic cholestasis. Preclinical neuroprotective and anti-ER stress data is extensive. Improves insulin sensitivity in obese subjects.

• Potent hepatoprotective bile acid
• Reduces ER stress and supports protein folding
• Neuroprotective in preclinical models
• May improve insulin sensitivity

250–1500 mg daily. Liver support typically 500–1000 mg. Take with or without food.

• Diarrhea at high doses
• Mild GI discomfort
• Generally well tolerated

May interact with other bile acid therapies. Could theoretically affect absorption of fat-soluble medications.

Prescription-grade TUDCA differs from OTC supplements in purity and dosing. Neuroprotective human data is limited.

• Longevity55
• Recovery40